More than one-third of H7N9 avian influenza tested in a new study was resistant to the antiviral drugs Tamiflu (oseltamivir) and Relenza (zanamivir), and lab tests failed to detect the resistance, making it tough to monitor, a new study says. "If H7N9 does acquire human-to-human transmissibility, what do we have to treat it with until we have a vaccine? Oseltamivir. We would be in big trouble," said researcher Robert Webster. "We'd better get some vaccine seed stocks up and ready. The antiviral option for controlling H7N9 isn't too good."
Published in Brief: